TriSalus Life Sciences, Inc. (NASDAQ:TLSI) Receives Average Rating of “Hold” from Brokerages

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) has earned an average rating of “Hold” from the five ratings firms that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation and three have given a buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $8.6667.

TLSI has been the subject of a number of recent research reports. Lake Street Capital dropped their price objective on shares of TriSalus Life Sciences from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday, May 13th. HC Wainwright assumed coverage on shares of TriSalus Life Sciences in a research note on Wednesday. They set a “buy” rating and a $11.00 price objective for the company. Weiss Ratings restated a “sell (e+)” rating on shares of TriSalus Life Sciences in a report on Friday, August 7th. Finally, Wall Street Zen raised shares of TriSalus Life Sciences from a “sell” rating to a “hold” rating in a research note on Sunday, August 23rd.

Institutional Trading of TriSalus Life Sciences

A number of hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. lifted its position in shares of TriSalus Life Sciences by 35,804.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 7,540 shares of the company’s stock worth $41,000 after purchasing an additional 7,519 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new position in shares of TriSalus Life Sciences during the second quarter valued at about $47,000. Cura Wealth Advisors LLC purchased a new position in shares of TriSalus Life Sciences in the second quarter worth $36,000. Invesco Ltd. acquired a new stake in TriSalus Life Sciences during the 4th quarter worth about $72,000. Finally, Abel Hall LLC purchased a new stake in TriSalus Life Sciences in the fourth quarter valued at approximately $73,000. 2.58% of the stock is owned by hedge funds and other institutional investors.

TriSalus Life Sciences Stock Down 5.4%

TLSI opened at $4.73 on Wednesday. TriSalus Life Sciences has a 1-year low of $2.20 and a 1-year high of $7.95. The firm’s 50 day simple moving average is $4.75 and its two-hundred day simple moving average is $4.33. The company has a current ratio of 5.35, a quick ratio of 4.97 and a debt-to-equity ratio of 5.05. The company has a market capitalization of $291.25 million, a PE ratio of -3.64 and a beta of 0.44.

TriSalus Life Sciences (NASDAQ:TLSI) last released its earnings results on Thursday, August 6th. The company reported ($0.16) EPS for the quarter, hitting the consensus estimate of ($0.16). The company had revenue of $11.41 million during the quarter, compared to analysts’ expectations of $10.27 million.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc is a clinical-stage biotechnology company focused on the development and commercialization of non-invasive drug–device combination therapies for oncology applications. Leveraging proprietary electroporation and ultrasound platforms, the company aims to enhance the localized delivery and efficacy of established chemotherapeutic agents while reducing systemic toxicity. Its lead programs target hard-to-treat head and neck cancers, where improved tumor control and patient tolerability remain significant unmet needs.

The company’s pipeline comprises investigational product candidates in early and mid-stage clinical trials, including studies that combine its electrochemotherapy platform with radiation therapy and immuno-oncology agents.